The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
These stocks are already big winners in 2023 and should keep their momentum going in a new bull market.
Vertex Pharmaceuticals (NASDAQ: VRTX) has come a long way in the past ten years. In a little over a decade, the company has built a cystic fibrosis (CF) empire, commercializing four drugs for the disease that together generate blockbuster revenue . Now, whether you're a Vertex investor or a potential one, you may be wondering what's next for this big biotech.